Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on gene therapy for rare, severely debilitating diseases. The company develops ex vivo lentiviral vector therapies and in vivo adeno-associated virus candidates, giving it the profile of a small-cap clinical-stage drug developer rather than a commercial biopharma company.
Today's Snapshot
RCKT is trading 4% below yesterday's close, while its sector was flat.
Trading Volume
Below 10d avg (1.3M)
559.3K
vs S&P 500 Today
Strong Underperformance
-3.44%
Updated: September 10, 2026 at 16:55 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.52 - $3.67Sell
- RSI (14)45.83Neutral
- Stochastic %K (14, 3, 3)37.69Neutral
- MACD Level (12, 26)0.06Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.